Over the past few weeks, glucagon-like peptide-1 agonist (GLP-1) drug manufacturers Eli Lilly and Novo Nordisk have been sending cease and desist notices to providers that are still advertising generic, compounded versions of their brand name diabetes and weight loss drugs. A shortage of GLP-1 drugs temporarily allowed compounding pharmacies to produce their own versions, but now with the shortage over, the pharmacies must stop and return to filling prescriptions with the manufacturers’ branded products. …
Read More